[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363786-105":59,"doc-detail-363786-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evaluation-of-p53-expression-in-megakaryocytes-enhances-detection-of-tp53-mutations-and-residual-disease-in-myeloid-neoplasms","Evaluation of p53 Expression in Megakaryocytes Enhances Detection of TP53 Mutations and Residual Disease in Myeloid Neoplasms","","Study evaluates p53 expression in megakaryocytes (MKs) versus total bone marrow cells (TBMCs) to improve detection of TP53 mutations and residual disease in myeloid neoplasms. Background focuses on poor outcomes in TP53-mutated disease and the limited evidence for immunohistochemistry (IHC) assessment in treated cases. Methods analyze 214 patients (acute myeloid leukemia, myelodysplastic neoplasm, and negative controls), correlating p53 IHC in MKs and TBMCs with TP53 mutational status. Results show higher p53 expression in TP53-mutated cases at diagnosis/recurrence, with improved IHC specificity and supportive correlation to genetic and flow cytometry findings in treated patients. Conclusion positions p53 IHC as a rapid, cost-effective, reliable tool, especially where molecular testing access is limited.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-p53-expression-in-megakaryocytes-enhances-detection-of-tp53-mutations-and-residual-disease-in-myeloid-neoplasms/363786/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-p53-expression-in-megakaryocytes-enhances-detection-of-tp53-mutations-and-residual-disease-in-myeloid-neoplasms/363786.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of evaluating p53 expression in megakaryocytes?","Question",{"text":113,"@type":114},"The study assesses whether p53 staining in megakaryocytes, compared with total bone marrow cells, improves detection of TP53 mutation status and residual disease in myeloid neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patient cases are included and what types of diseases are evaluated?",{"text":118,"@type":114},"A total of 214 patients are evaluated, including acute myeloid leukemia, myelodysplastic neoplasm, and negative controls; additional treated TP53-mutated cases are included for residual disease assessment.",{"name":120,"@type":111,"acceptedAnswer":121},"What do the results show about p53 IHC in TP53-mutated versus TP53 wild-type cases?",{"text":122,"@type":114},"p53 expression in both megakaryocytes and total bone marrow cells is significantly higher in TP53-mutated cases than in TP53 wild-type and negative control groups at diagnosis or recurrence.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363786,1790173233,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review began 05/04/2026  \nReview ended 05/14/2026  \nPublished 06/02/2026  \n© Copyright 2026  \nGao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.110130  \nOpen Access Original Article  \nEvaluation of p53 Expression in Megakaryocytes Enhances Detection ofTP53 Mutations and Residual Disease in Myeloid Neoplasms  \nLinlin Gao 1, Jonah S. Rong 2 , Da Zhang 3 , Janet Woodroof 4, Wei Cui 3  \n1. Department of Pathology and Laboratory Medicine, Veterans Affairs (VA) Medical Center, Kansas City, USA 2. Science, Pembroke Hill School, Kansas City, USA 3. Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, Kansas City, USA 4. Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, USA  \nCorresponding author: Wei Cui, [wcui@kumc.edu](wcui@kumc.edu)  \nAbstract  \nBackground and objective: Patients with TP53-mutated myeloid neoplasms have poor clinical outcomes, and studies evaluating p53 expression by immunohistochemistry (IHC) in treated disease are limited. This is the first study to assess p53 expression in megakaryocytes (MKs) compared with total bone marrow cells (TBMCs) and to examine its association with TP53 mutation status in both newly diagnosed/recurrent myeloid neoplasms and treated cases with residual disease.  \nMethods: We evaluated 214 patients, including 130 with acute myeloid leukemia (AML), 61 with myelodysplastic neoplasm (MDS), and 23 negative controls. p53 expression by IHC was assessed in MKs and TBMCs and correlated with TP53 mutational status.  \nResults: p53 expression in both MKs and TBMCs was significantly higher in TP53-mutated myeloid neoplasms than in TP53 wild-type cases and negative controls at diagnosis/recurrence. Evaluation of MKs improved IHC specificity from 0.91 to 0.98. In treated TP53-mutated cases, p53 expression in MKs and TBMCs correlated well with genetic and flow cytometry findings, with MK assessment also slightly improving sensitivity.  \nConclusion: p53 IHC is a rapid, cost-effective, and reliable tool for detecting TP53 aberrations and residual disease in myeloid neoplasms, particularly in settings with limited access to molecular testing. Concurrent evaluation of p53 expression in MKs and TBMCs improves both diagnostic specificity and sensitivity.  \nCategories: Hematology, Pathology, Oncology  \nKeywords: acute myeloid leukemia, immunohistochemistry, myelodysplastic syndrome, myeloid neoplasm, p53,  \nresidual disease, tp53  \nIntroduction  \nThe tumor suppressor p53 plays a critical role in preserving genomic integrity and cellular stability by regulating cell cycle arrest, facilitating DNA repair, and promoting apoptosis. The TP53 gene is one of the most frequently altered genes in human cancers [1-4]. TP53 mutations are present in ~5-10% of  \nmyelodysplastic neoplasms (MDS) and ~7-15% of de novo acute myeloid leukemia (AML) but are more common in therapy-related disease, reaching frequencies of up to 40%[5-7]. The classifications of MDS with biallelic TP53 inactivation and myeloid neoplasms with mutated TP53 were introduced in the 2022 World Health Organization (WHO) and International Consensus Classifications (ICC) [8,9] . In AML and MDS, TP53 mutations are associated with adverse cytogenetics and unfavorable clinical outcomes [10-13] . Furthermore, TP53-mutated AML and MDS with increased blasts share similar molecular characteristics and clinical  \noutcomes. They should be considered a distinct molecular disease entity [14].  \np53 protein expression has been utilized as an indirect indicator of TP53 mutation in MDS and AML [12, 15- 17]. In both MDS and de novo AML patients, a p53 expression level of 3+ nuclear staining in at least 5% of bone marrow cells (BMCs) was established as the ","cbCainHUxgLqUgRT","https://ap.wps.com/l/cbCainHUxgLqUgRT","pdf",2524092,"English","# Introduction\n## p53 and TP53 mutations in myeloid neoplasms\n## p53 IHC as an indicator of TP53 mutation\n# Materials And Methods\n## Case selection\n## p53 IHC assessment in MKs and TBMCs","[{\"question\":\"What is the purpose of evaluating p53 expression in megakaryocytes?\",\"answer\":\"The study assesses whether p53 staining in megakaryocytes, compared with total bone marrow cells, improves detection of TP53 mutation status and residual disease in myeloid neoplasms.\"},{\"question\":\"How many patient cases are included and what types of diseases are evaluated?\",\"answer\":\"A total of 214 patients are evaluated, including acute myeloid leukemia, myelodysplastic neoplasm, and negative controls; additional treated TP53-mutated cases are included for residual disease assessment.\"},{\"question\":\"What do the results show about p53 IHC in TP53-mutated versus TP53 wild-type cases?\",\"answer\":\"p53 expression in both megakaryocytes and total bone marrow cells is significantly higher in TP53-mutated cases than in TP53 wild-type and negative control groups at diagnosis or recurrence.\"}]","Evaluation of p53 Expression in Megakaryocytes Enhances Detection of TP53 Mutations and Residual Disease in Myeloid Neoplasms | PDF",1790153137,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0db77adf566353d1d72f44901d141ce.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/200f216d9a0dc1f1399f67c55159f546.webp",982,1389,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b63cce3cd2808967247ccb567f49dfc7.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c69f7a03935a732e9f94ff5b381fc7c.webp",980,1386]